STARNBERG, Germany, March 20, 2017 /PRNewswire/ -- PARI Pharma, a company focused on optimization of drug-device combinations, has licensed its first-in-class inhalation development program for ...

MONTEREY, Calif., Nov. 26 PARI Pharma's eFlow electronicnebulizer was included in Gilead's (Nasdaq: GILD) recent New Drug Application(NDA) submittal to the U.S. Food and Drug Administration (FDA) for ...

STARNBERG, Germany, March 20, 2017 /PRNewswire/ --PARI Pharma, a company focused on optimization of drug-device combinations, has licensed its first-in-class inhalation development program for ...

MONTEREY, Calif., Oct. 6 Today, PARI Pharma GmbH willunveil a prototype Closed System using eFlow Technology that uses single doseampoules to control medication used in the nebulizer system. By ...

MONTEREY, Calif., April 17 /PRNewswire/ -- An optimized PARI eFlow platform nebulizer will be delivering Alnylam's ALN-RSV01 in a Phase II human clinical trial that has begun enrolling patients.

PARI's eFlow, an advanced electronic nebulizer, was optimized and used to deliver Alnylam's ALN-RSV01 in a Phase I human clinical trial. Results of the Phase I trial were announced at the 18th Annual ...

STARNBERG, Germany, June 7, 2016 /PRNewswire/ -- PARI Pharma, a company focused on the development of advanced aerosol therapies using eFlow Technology, announces that its proprietary closed eFlow ...

As highlighted in the April issue of Medical Device & Diagnostic Industry magazine, PARI Aerosol Research Institute has been awarded a 2006 Medical Design Excellence Award for eFlow. eFlow is an ...

LANGHORNE, Pa., December 02, 2025--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European ...